Related Experiment Video
Updated: Jul 5, 2026
09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Developing therapeutic immunoglobulins: European regulatory perspectives and implications
1Regulatory Affairs, CSL Behring AG, Bern, Switzerland. kurz@lycos.com
Summary
Therapeutic immunoglobulins, derived from human blood, treat infections and autoimmune diseases by providing antibodies. This review covers their EU licensure, manufacturing, and safety regulations.
Area of Science:
- Immunology
- Pharmacology
- Regulatory Science
Background:
- Therapeutic immunoglobulins are derived from pooled human plasma, containing a broad spectrum of natural antibodies.
- They are crucial for preventing infections in individuals with compromised immune systems, such as primary immunodeficiencies.
- Beyond immunodeficiencies, these therapies are utilized for autoimmune conditions like immune thrombocytopenic purpura, Guillain Barré syndrome, and Kawasaki disease.
Purpose of the Study:
- To review the conditions for licensure of therapeutic immunoglobulins in the European Union.
- To discuss regulatory issues and procedures pertinent to immunoglobulin products.
- To highlight regulatory expectations regarding manufacturing, control, safety, and efficacy.
Main Methods:
- Review of European pharmaceutical legislation and regulatory guidelines.
- Analysis of public information concerning immunoglobulin products.
- Examination of safety and efficacy requirements for market authorization.
Main Results:
- Detailed overview of EU regulatory requirements for therapeutic immunoglobulins.
- Emphasis on manufacturing controls and quality assurance standards.
- Description of safety and efficacy data necessary for licensure.
Conclusions:
- Adherence to stringent regulatory standards is essential for the approval and use of therapeutic immunoglobulins.
- The review provides a comprehensive guide to navigating EU regulations for these vital biological products.
- Understanding regulatory expectations ensures the safety and efficacy of immunoglobulins for patient treatment.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
10:50Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
Published on: May 1, 2019
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).